Glioblastoma and meningioma biology: targeted therapy and oncolytic virus therapy

Fares Nigim

Research output: ThesisDoctoral ThesisExternal prepared

Abstract

In my PhD research I tackled a number of projects and this included: a new glioblastoma model with palisading necrosis, hypervascularity, and hypoxia, and treatment with HIF-1a inhibitor digoxin; a patient-derived malignant meningioma model that is tumorigenic in immune-deficient mice treated with oncolytic herpes simplex virus; targeting high grade meningioma with a b1 integrin antagonizing antibody; studied TGF-beta pathway in a multiple glioblastoma models and combined antagonists of TGF-beta pathway with oncolytic herpes simplex virus; and studied AS1411, the first oligodeoxynucleotide aptamer to reach clinical trials in many cancers, and found the mechanism by which it inhibits the growth of glioma cells and improve survival of mice bearing glioblastoma. Finally, I bridged all of my experimental work with introduction, discussion and conclusion as well as a review on novel therapies for meningiomas.
Original languageEnglish
Awarding Institution
  • Maastricht University
Supervisors/Advisors
  • Temel, Yasin, Supervisor
  • Rabkin, S.D., Supervisor, External person
  • Wakimoto, Hiroaki, Advisor, External person
  • Ackermans, Linda, Advisor
Award date20 Dec 2019
Publication statusPublished - 2019

Keywords

  • Cancer Biology
  • Brain Cancer
  • Targeted Therapy
  • Oncolytic Virus Therapy
  • Preclinical Cancer Animal Models
  • Cutting Edge Cancer Treatment

Cite this